Top Stocks Today : IIFL Securities has Buy call on J B Chemicals And Pharma - November 08

IIFL Securities maintains a 'buy' rating on J B Chemicals And Pharma, setting a target price of Rs 2285. The current market price of the stock stands at Rs 1842, indicating a potential upside of 23%. The brokerage cites the company's strong performance in the pharmaceutical sector, its focus on expanding its product portfolio, and its growing presence in the international markets as key factors supporting its bullish stance.

About J B Chemicals And Pharma:

J.B. Chemicals and Pharmaceuticals Limited (JBCPL) is a pharmaceutical company headquartered in Mumbai, India. Listed on the National Stock Exchange of India (NSE), the company operates in three main segments: Active Pharmaceutical Ingredients (APIs), Contract Development and Manufacturing Organization (CDMO), and Branded Formulations. JBCPL manufactures a wide range of APIs, including antibiotics, intermediates, and vitamins, and provides CDMO services to pharmaceutical companies worldwide. The Branded Formulations division focuses on branded generic and over-the-counter medicines in India, targeting the gastro-intestinal, cardiovascular, and respiratory therapeutic areas.

52 Week Price Trend:

J B Chemicals And Pharma (NSE: JBCHEPHARM), a leading pharmaceutical company, has witnessed significant stock price movement over the past year. As of July 18, 2023, the CMP stands at Rs 1842, indicating a substantial increase from the 52-week low of Rs 875. While it has not yet surpassed its 52-week high of Rs 1940, the stock has shown steady growth and outperformed the broader market. This positive trajectory reflects the company's strong fundamentals, including a robust product portfolio, expansion into new markets, and strategic alliances, making it an attractive investment opportunity in the healthcare sector.

Stratzy's MOST Analysis:

JBCHEPHARM has received a rating of BB by Stratzy's MOST framework, indicating a Medium Fundamental Risk level. This rating is based on an assessment of the company's Management, Outlook, Safety, and Trend. Specifically, the rating reflects concerns regarding the company's management team and its overall outlook. However, the company's financial safety and market trend are considered to be relatively stable.

Company's Fundamentals:

J B Chemicals And Pharma (NSE: JBCHEPHARM), a pharmaceutical company listed on the National Stock Exchange (NSE), currently exhibits a stock PE ratio of 49.71, indicating that investors pay approximately 49.71 times the company's annual earnings per share. This suggests that the stock is priced higher relative to its earnings. The price-to-book (PB) ratio of 9.4 implies that the market value of the company's assets is about 9.4 times its book value, suggesting the stock may be relatively overvalued. Despite these valuations, JB Chemicals And Pharma pays a modest dividend yield of 0.54%, which may provide some income to investors.

Fundamental and Technical information provided in this blog were last updated on 08 Nov, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.